Search
SOLACI Congress
HomeStructural heart diseaseValvular Aortic valve

Valvular Aortic valve

View Category

Structural heart disease

Aortic Stenosis and Dialysis: Is TAVR the Strategy of Choice?

Courtesy of Dr. Carlos Fava. TAVR has been shown beneficial in high and moderate risk patients, but there...
solaci -
Learn More
Structural heart disease

CoreValve US Pivotal High Risk Trial: at 5 years, similar results

Courtesy of Dr. Carlos Fava. We are well aware of transcatheter aortic valve replacement’s (TAVR) effect in high-risk...
solaci -
Learn More
Structural heart disease

Surprises in the Physiopathology of Critical Ischemia

Luminal thrombotic occlusions associated with non-significant atherosclerosis are commonly observed in patients with critical lower limb ischemia,...
solaci -
Learn More
Structural heart disease

Differences in Stroke between TAVR and SAVR in Intermediate Risk Patients

Transcatheter aortic valve replacement (TAVR) is more and more frequent in lower risk populations that had previously...
solaci -
Learn More
Structural heart disease

TAVR in Low-Risk Patients with “Zero” Mortality and “Zero” Stroke

Transcatheter aortic valve replacement (TAVR) is now the standard of care for patients with symptomatic severe aortic...
solaci -
Learn More
Structural heart disease

How to predict post TAVR quality of life in “real world” patients

Despite the benefit for most patients, a small number of patients still show poor outcomes after transcatheter...
solaci -
Learn More
Chronic Ischemic cardiopathy

What Should We Use for the Functional Assessment of Coronary Lesions in Severe Aortic Stenosis?

This systematic analysis measured intracoronary pressure in different phases of the cardiac cycle and flow velocity in...
solaci -
Learn More
Antithrombotic Anticoagulants

Galileo: Rivaroxaban After TAVR Stopped Due to Early Event Rates

Patients undergoing transcatheter aortic valve replacement (TAVR) randomized to rivaroxaban in the GALILEO trial experienced higher risk...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Dr. Juan Manuel Pérez - 0
Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

Endoleaks after endovascular repair of complex aortic aneurysms: always reintervene or monitor with CTA?

Dr. Juan Manuel Pérez - 0
Endovascular repair of thoracoabdominal aneurysms requiring sealing above the renal arteries, with preservation of visceral vessels using fenestrated and/or branched devices (F/B-EVAR), has become...

Is it safe to use negative chronotropic drugs early after TAVI?

Dr. Juan Manuel Pérez - 0
TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy